CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31
CareDx, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$67.08+3.08 (+4.81%)
Close on Oct 19, 2026
- Market cap
- $3.58B
- P/E (TTM)
- 32.4
- Dividend yield
- –
CareDx, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing services revenue | $341.87M | $303.97M | $274.50M | $259.94M | $248.58M | $257.47M | $249.38M | $232.27M | $219.24M | $201.74M | $209.69M | $228.40M | 74.6% | +37.5% |
| Patient and digital solutions revenue | $67.35M | $60.94M | $56.93M | $51.57M | $48.02M | $45.96M | $43.62M | $41.85M | $39.86M | $38.12M | $37.12M | $35.91M | 14.7% | +40.2% |
| Product revenue | $48.87M | $47.91M | $48.38M | $46.49M | $44.22M | $43.00M | $40.78M | $38.66M | $37.98M | $35.25M | $33.52M | $32.83M | 10.7% | +10.5% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $438.71M | $393.72M | $359.94M | $338.74M | $322.76M | $329.09M | $317.73M | $297.64M | $281.75M | $260.26M | $265.63M | $282.12M | 95.8% | +35.9% |
| Europe | – | – | – | – | – | – | $10.67M | $10.18M | $10.14M | $9.93M | $10.17M | $9.90M | – | – |
From the segment and revenue-disaggregation notes of CareDx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.